TECX Intrinsic Valuation and Fundamental Analysis - AVROBIO Inc - Alpha Spread

AVROBIO Inc
NASDAQ:TECX

Watchlist Manager
AVROBIO Inc Logo
AVROBIO Inc
NASDAQ:TECX
Watchlist
Price: 18.28 USD 1.61%
Market Cap: 269.3m USD
Have any thoughts about
AVROBIO Inc?
Write Note

Intrinsic Value

TECX's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one TECX stock under the Base Case scenario is 6.65 USD. Compared to the current market price of 18.28 USD, AVROBIO Inc is Overvalued by 64%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TECX Intrinsic Value
6.65 USD
Overvaluation 64%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
AVROBIO Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling TECX based on its intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?
How do you feel about TECX?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Wall St Estimates
Price Target
Loading
Revenue Forecast
Operating Income Forecast
Earnings Forecast
No Indicators Selected
Select Indicators
Investor Returns
Shareholder Yield
Dividend Safety
Dividend Yield
Dividend Payout Ratio
Buyback Yield
Debt Paydown Yield
No Indicators Selected
Select Indicators
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about AVROBIO Inc

Provide an overview of the primary business activities
of AVROBIO Inc.

What unique competitive advantages
does AVROBIO Inc hold over its rivals?

What risks and challenges
does AVROBIO Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for AVROBIO Inc.

Provide P/S
for AVROBIO Inc.

Provide P/E
for AVROBIO Inc.

Provide P/OCF
for AVROBIO Inc.

Provide P/FCFE
for AVROBIO Inc.

Provide P/B
for AVROBIO Inc.

Provide EV/S
for AVROBIO Inc.

Provide EV/GP
for AVROBIO Inc.

Provide EV/EBITDA
for AVROBIO Inc.

Provide EV/EBIT
for AVROBIO Inc.

Provide EV/OCF
for AVROBIO Inc.

Provide EV/FCFF
for AVROBIO Inc.

Provide EV/IC
for AVROBIO Inc.

Show me price targets
for AVROBIO Inc made by professional analysts.

What are the Revenue projections
for AVROBIO Inc?

How accurate were the past Revenue estimates
for AVROBIO Inc?

What are the Net Income projections
for AVROBIO Inc?

How accurate were the past Net Income estimates
for AVROBIO Inc?

What are the EPS projections
for AVROBIO Inc?

How accurate were the past EPS estimates
for AVROBIO Inc?

What are the EBIT projections
for AVROBIO Inc?

How accurate were the past EBIT estimates
for AVROBIO Inc?

Compare the revenue forecasts
for AVROBIO Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of AVROBIO Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of AVROBIO Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of AVROBIO Inc compared to its peers.

Compare the P/E ratios
of AVROBIO Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing AVROBIO Inc with its peers.

Analyze the financial leverage
of AVROBIO Inc compared to its main competitors.

Show all profitability ratios
for AVROBIO Inc.

Provide ROE
for AVROBIO Inc.

Provide ROA
for AVROBIO Inc.

Provide ROIC
for AVROBIO Inc.

Provide ROCE
for AVROBIO Inc.

Provide Gross Margin
for AVROBIO Inc.

Provide Operating Margin
for AVROBIO Inc.

Provide Net Margin
for AVROBIO Inc.

Provide FCF Margin
for AVROBIO Inc.

Show all solvency ratios
for AVROBIO Inc.

Provide D/E Ratio
for AVROBIO Inc.

Provide D/A Ratio
for AVROBIO Inc.

Provide Interest Coverage Ratio
for AVROBIO Inc.

Provide Altman Z-Score Ratio
for AVROBIO Inc.

Provide Quick Ratio
for AVROBIO Inc.

Provide Current Ratio
for AVROBIO Inc.

Provide Cash Ratio
for AVROBIO Inc.

What is the historical Revenue growth
over the last 5 years for AVROBIO Inc?

What is the historical Net Income growth
over the last 5 years for AVROBIO Inc?

What is the current Free Cash Flow
of AVROBIO Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for AVROBIO Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
AVROBIO Inc

Balance Sheet Decomposition
AVROBIO Inc

Current Assets 187.4m
Cash & Short-Term Investments 185.1m
Other Current Assets 2.3m
Non-Current Assets 6.5m
PP&E 5.9m
Other Non-Current Assets 600k
Current Liabilities 26m
Accounts Payable 4.1m
Accrued Liabilities 20.6m
Other Current Liabilities 1.4m
Non-Current Liabilities 1.5m
Long-Term Debt 637k
Other Non-Current Liabilities 905k
Efficiency

Earnings Waterfall
AVROBIO Inc

Revenue
0 USD
Operating Expenses
-56m USD
Operating Income
-56m USD
Other Expenses
-2.2m USD
Net Income
-58.3m USD

Free Cash Flow Analysis
AVROBIO Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

TECX Profitability Score
Profitability Due Diligence

AVROBIO Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

AVROBIO Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

TECX Solvency Score
Solvency Due Diligence

AVROBIO Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Negative Net Debt
Low D/E
69/100
Solvency
Score

AVROBIO Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TECX Price Targets Summary
AVROBIO Inc

Wall Street analysts forecast TECX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TECX is 61.2 USD with a low forecast of 49.49 USD and a high forecast of 79.8 USD.

Lowest
Price Target
49.49 USD
171% Upside
Average
Price Target
61.2 USD
235% Upside
Highest
Price Target
79.8 USD
337% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for TECX?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for TECX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Want to learn more about TECX dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

TECX Price
AVROBIO Inc

1M 1M
+7%
6M 6M
+2 284 900%
1Y 1Y
+2 031 011%
3Y 3Y
+493 954%
5Y 5Y
+2 031 011%
10Y 10Y
+1 218 567%
Annual Price Range
18.28
52w Low
0.0007
52w High
19.2
Price Metrics
Average Annual Return 85.03%
Standard Deviation of Annual Returns 117.42%
Max Drawdown -33%
Shares Statistics
Market Capitalization 265.1m USD
Shares Outstanding 14 730 000
Percentage of Shares Shorted
N/A

Competitive Landscape

Profile

AVROBIO Inc Logo
AVROBIO Inc

Country

United States of America

Industry

Biotechnology

Market Cap

265.1m USD

Dividend Yield

0%

Description

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The firm is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of five lentiviral-based gene therapy programs, which include AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3, and AVR-RD-03 for the treatment of Pompe disease.

Contact

MASSACHUSETTS
Cambridge
1 Kendall Sq Bldg 300 Ste 201
+17819626030.0
www.avrobio.com

IPO

2018-06-21

Employees

122

Officers

See Also

Discover More
What is the Intrinsic Value of one TECX stock?

The intrinsic value of one TECX stock under the Base Case scenario is 6.65 USD.

Is TECX stock undervalued or overvalued?

Compared to the current market price of 18.28 USD, AVROBIO Inc is Overvalued by 64%.

Back to Top